(EXAS) EXACT Sciences - Ratings and Ratios
Colon, Breast, Biomarker, Tumor, Genetics
EXAS EPS (Earnings per Share)
EXAS Revenue
Description: EXAS EXACT Sciences
Exact Sciences Corporation is a biotechnology company specializing in cancer screening and diagnostic tests. The companys flagship product, Cologuard, is a non-invasive stool-based DNA screening test for colorectal cancer and pre-cancer. Additionally, Exact Sciences offers a range of Oncotype DX tests for breast, colon, and other cancers, providing recurrence score and tumor profiling information to guide treatment decisions.
From a business perspective, Exact Sciences has established strategic partnerships with reputable institutions such as the Mayo Foundation for Medical Education and Research and Johns Hopkins University, underscoring its commitment to advancing cancer diagnostics. The companys pipeline is focused on developing innovative screening and diagnostic products across the cancer care continuum, from risk assessment to recurrence monitoring.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, test adoption rates, and expansion into new markets are crucial. Notably, Exact Sciences has seen significant revenue growth driven by the adoption of Cologuard and Oncotype DX tests. As of the latest available data, the companys revenue has consistently grown, driven by increasing demand for its cancer diagnostic tests. Furthermore, the companys ability to expand its product offerings and penetrate new markets will be critical to its long-term success.
From a financial perspective, Exact Sciences market capitalization stands at approximately $9.5 billion, with a forward price-to-earnings ratio indicating significant growth expectations. However, the companys return on equity (ROE) is currently negative, reflecting substantial investment in research and development, as well as commercialization efforts. As the company continues to execute on its pipeline and grow its revenue, improvements in ROE can be expected.
Overall, Exact Sciences Corporation is well-positioned in the cancer diagnostics market, with a strong portfolio of products and a commitment to innovation. As the company continues to execute on its strategic objectives, investors will be watching key KPIs such as revenue growth, test adoption rates, and pipeline progress to gauge its success.
EXAS Stock Overview
| Market Cap in USD | 9,328m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2001-02-01 |
EXAS Stock Ratings
| Growth Rating | -20.2% |
| Fundamental | 45.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.0% |
| Analyst Rating | 4.54 of 5 |
EXAS Dividends
Currently no dividends paidEXAS Growth Ratios
| Growth Correlation 3m | -20.7% |
| Growth Correlation 12m | -59.1% |
| Growth Correlation 5y | -64.2% |
| CAGR 5y | 13.13% |
| CAGR/Max DD 3y | 0.22 |
| CAGR/Mean DD 3y | 0.37 |
| Sharpe Ratio 12m | -1.64 |
| Alpha | 0.00 |
| Beta | 0.980 |
| Volatility | 47.73% |
| Current Volume | 2233.5k |
| Average Volume 20d | 2440.7k |
| Stop Loss | 50.2 (-4.2%) |
| Signal | 0.14 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-1.01b TTM) > 0 and > 6% of Revenue (6% = 176.4m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 33.54% (prev 30.01%; Δ 3.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 305.6m > Net Income -1.01b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (188.9m) change vs 12m ago 2.49% (target <= -2.0% for YES) |
| Gross Margin 68.19% (prev 72.30%; Δ -4.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.15% (prev 39.14%; Δ 8.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -26.57 (EBITDA TTM -818.5m / Interest Expense TTM 37.5m) >= 6 (WARN >= 3) |
Altman Z'' -4.00
| (A) 0.17 = (Total Current Assets 1.51b - Total Current Liabilities 521.9m) / Total Assets 5.80b |
| (B) -0.79 = Retained Earnings (Balance) -4.60b / Total Assets 5.80b |
| (C) -0.16 = EBIT TTM -997.2m / Avg Total Assets 6.24b |
| (D) -1.38 = Book Value of Equity -4.60b / Total Liabilities 3.33b |
| Total Rating: -4.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 45.76
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 1.57% = 0.78 |
| 3. FCF Margin 5.77% = 1.44 |
| 4. Debt/Equity 0.95 = 2.06 |
| 5. Debt/Ebitda -2.88 = -2.50 |
| 6. ROIC - WACC (= -27.44)% = -12.50 |
| 7. RoE -38.37% = -2.50 |
| 8. Rev. Trend 95.88% = 7.19 |
| 9. EPS Trend 65.57% = 3.28 |
What is the price of EXAS shares?
Over the past week, the price has changed by -4.36%, over one month by +16.17%, over three months by -0.30% and over the past year by -22.96%.
Is EXACT Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXAS is around 42.83 USD . This means that EXAS is currently overvalued and has a potential downside of -18.23%.
Is EXAS a buy, sell or hold?
- Strong Buy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXAS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63.1 | 20.5% |
| Analysts Target Price | 63.1 | 20.5% |
| ValueRay Target Price | 47.4 | -9.4% |
Last update: 2025-09-04 04:37
EXAS Fundamental Data Overview
CCE Cash And Equivalents = 858.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 65.3595
P/S = 3.1728
P/B = 3.6807
P/EG = -1.07
Beta = 0.928
Revenue TTM = 2.94b USD
EBIT TTM = -997.2m USD
EBITDA TTM = -818.5m USD
Long Term Debt = 2.32b USD (from longTermDebt, last quarter)
Short Term Debt = 31.3m USD (from shortTermDebt, last quarter)
Debt = 2.36b USD (Calculated: Short Term 31.3m + Long Term 2.32b)
Net Debt = 1.86b USD (from netDebt column, last quarter)
Enterprise Value = 10.82b USD (9.33b + Debt 2.36b - CCE 858.4m)
Interest Coverage Ratio = -26.57 (Ebit TTM -997.2m / Interest Expense TTM 37.5m)
FCF Yield = 1.57% (FCF TTM 169.6m / Enterprise Value 10.82b)
FCF Margin = 5.77% (FCF TTM 169.6m / Revenue TTM 2.94b)
Net Margin = -34.19% (Net Income TTM -1.01b / Revenue TTM 2.94b)
Gross Margin = 68.19% ((Revenue TTM 2.94b - Cost of Revenue TTM 935.2m) / Revenue TTM)
Tobins Q-Ratio = -2.36 (set to none) (Enterprise Value 10.82b / Book Value Of Equity -4.60b)
Interest Expense / Debt = 0.42% (Interest Expense 9.84m / Debt 2.36b)
Taxrate = 21.0% (US default)
NOPAT = -997.2m (EBIT -997.2m, no tax applied on loss)
Current Ratio = 2.89 (Total Current Assets 1.51b / Total Current Liabilities 521.9m)
Debt / Equity = 0.95 (Debt 2.36b / last Quarter total Stockholder Equity 2.47b)
Debt / EBITDA = -2.88 (Net Debt 1.86b / EBITDA -818.5m)
Debt / FCF = 13.89 (Debt 2.36b / FCF TTM 169.6m)
Total Stockholder Equity = 2.62b (last 4 quarters mean)
RoA = -17.34% (Net Income -1.01b, Total Assets 5.80b )
RoE = -38.37% (Net Income TTM -1.01b / Total Stockholder Equity 2.62b)
RoCE = -20.17% (Ebit -997.2m / (Equity 2.62b + L.T.Debt 2.32b))
RoIC = -19.68% (NOPAT -997.2m / Invested Capital 5.07b)
WACC = 7.76% (E(9.33b)/V(11.68b) * Re(9.63%)) + (D(2.36b)/V(11.68b) * Rd(0.42%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 0.59%
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 63.64% ; FCFE base≈114.5m ; Y1≈75.2m ; Y5≈34.4m
Fair Price DCF = 2.80 (DCF Value 530.2m / Shares Outstanding 189.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 65.57 | EPS CAGR: 233.4% | SUE: 0.66 | # QB: 0
Revenue Correlation: 95.88 | Revenue CAGR: 17.29% | SUE: 3.56 | # QB: 2
Additional Sources for EXAS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle